Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines

Keisuke Taniguchi (✉ keisuke-taniguchi@yakult.co.jp)

Yakult Central Institute, Yakult Honsha Co., Ltd., Tokyo

Hiroaki Konishi

Yakult Central Institute, Yakult Honsha Co., Ltd., Tokyo

Akiko Yoshinaga

Yakult Central Institute, Yakult Honsha Co., Ltd., Tokyo

Momomi Tsugane

Yakult Central Institute, Yakult Honsha Co., Ltd., Tokyo

Hiroyuki Takahashi

Pharmaceutical Department, Yakult Honsha Co., Ltd., Tokyo

Fukiko Nishisaka

Yakult Central Institute, Yakult Honsha Co., Ltd., Tokyo

Yoshiyuki Shishido

Yakult Central Institute, Yakult Honsha Co., Ltd., Tokyo

Akira Asai

Center for Drug Discovery, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka

Research Article

Keywords: transcription 3 (STAT3), cancer

Posted Date: December 23rd, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-123999/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Scientific Reports on March 23rd, 2021. See the published version at <https://doi.org/10.1038/s41598-021-86021-8>.

Abstract

Signal transducer and activator of transcription 3 (STAT3) plays a critical role in regulating cell growth, survival, and metastasis. STAT3 signaling is constitutively activated in various types of hematologic or solid malignancies. YHO-1701 has been developed as an orally available STAT3 inhibitor. Herein, YHO-1701 in combination with molecular-targeted agents was evaluated. Additive or synergistic effects were observed in a broad spectrum of “combination treatment + cell line” pairs. Of particular interest was the synergistic effect observed when YHO-1701 was combined with imatinib or dasatinib [breakpoint cluster region-abelson (BCR-ABL) inhibitors], osimertinib [epidermal growth factor receptor (EGFR) inhibitor], crizotinib, alectinib, or ceritinib [anaplastic lymphoma kinase (ALK) inhibitors]. The results further showed a close relationship between these synergistic effects and the cellular levels of the key molecules involved in the target pathways for YHO-1701 and each combination drug. The combination of YHO-1701 with alectinib resulted in a significantly greater antitumor activity without exhibiting body weight loss in an NCI-H2228 [echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion] xenograft mouse model. Our results strongly suggest that the logical strategy in combination with the novel STAT3 inhibitor YHO-1701 and other mechanistically different targeted agents could be a promising approach in the clinical setting.

Introduction

Aberrant constitutive activation of signal transducer and activator of transcription 3 (STAT3) has been documented at a high frequency in various malignant tumors^{1–5}. Persistent STAT3 activation has been attributed to the dysregulation of upstream tyrosine kinases and negative regulators in the STAT3 signaling pathway^{6,7}. STAT3 phosphorylation is conducive to malignancy by upregulating the expression of pro-oncogenes such as survivin, allowing tumor cells to survive and proliferate^{1–5}. Overexpression of phosphorylated STAT3 occurs in numerous tumors^{1–5}, suggesting that STAT3 inhibition is a promising approach for controlling cancers. STAT3 activation involves multiple signaling pathways within the tumor microenvironment, thus making the antiproliferative strategies of inhibitors targeting upstream molecules difficult. In other words, this implies that synergy by STAT3 inhibition may be expected with inhibitors to block these pathways.

We previously identified a novel orally active STAT3 inhibitor, YHO-1701. In SAS oral carcinoma cells, which are known for interleukin-6 signaling, YHO-1701 blocked multistep events accompanied by STAT3 dimerization, and YHO-1701 also exhibited an enhanced antitumor effect with the multikinase inhibitor sorafenib⁸. These findings reveal that STAT3 is an attractive target; this motivated us to conduct further testing of a drug combination. STAT3 is a crucial convergence point in several ligand/receptor pathways and nonreceptor tyrosine kinase pathways; thus, the consequent cross-talk among these signaling pathways may be conducive to sensitivity to molecular-targeted drugs such as breakpoint cluster region-abelson (BCR-ABL) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, and anaplastic lymphoma kinase (ALK) inhibitors (Fig. 1). For example, although most patients with echinoderm

microtubule-associated protein-like 4 (EML4)-ALK positive non-small cell lung cancer (NSCLC) derive advantage from treatment with ALK inhibitors, the clinical response to these drugs varies significantly among such individuals⁹. Cross-talking among the signaling pathways is complicated and requires further investigations; however, the underlying mechanisms of responses to ALK inhibitors have been identified only in recent years. These primarily include EML4-ALK gene aberrations (mutation or amplification)^{10–15}. Another commonly observed mechanism is the upregulation of substitute tyrosine kinases such as EGFR, KIT, and c-MET that could bypass the ALK signaling pathway^{14,16,17}. However, these findings do not necessarily explain all drug responses, and the molecular mechanisms underlying this insecurity remain uncertain. Therefore, further understanding of the signaling pathways is of immense importance to future clinical practice; we hypothesized that STAT3 signaling undertakes a vital role in limiting the antiproliferative response to various already-available targeted agents. Herein, we designed a combination strategy of molecular-targeted drugs with the new STAT3 inhibitor YHO-1701 to overcome the insufficiency in inducing potent antiproliferative responses. Furthermore, since STAT3 binds directly to the survivin promoter and regulates its expression¹⁸, we sought to determine the utility of the biomarker survivin for YHO-1701 treatment. Considering the aforementioned findings, targeting STAT3 signaling appears to be a novel approach to treat cancers.

Results

Identification of synergistic combinations in human cancer cell lines.

To expand our previous observations⁸, a total of 33 “combination + cell line” sets were evaluated with reference to previous research^{19,20}. A heat map is shown in Fig. 2 for YHO-1701 in combination with the already-available targeted agents for hematologic or solid malignancies. The combination activity pattern was complex, and additive or synergistic effects were observed in approximately two-thirds of the total number of combination treatments given, whereas antagonism was observed in the other pairs. Interestingly, the YHO-1701/sorafenib combination exhibited an antiproliferative synergistic effect in SAS oral cancer cells as noted elsewhere⁸. This combination and the combination with another multikinase inhibitor, vandetanib, also displayed synergistic inhibitory effects on the growth of both thyroid cancer cell lines. In contrast, YHO-1701 combined with trametinib (MEK inhibitor), vemurafenib, or dabrafenib (BRAF inhibitors) was not preferable, wherein only 4 of 11 drug–cell line pairs were additive or synergistic in the four melanoma cell lines. The combinations with BCR-ABL inhibitors against lymphoma cell lines and with ALK inhibitors against NSCLC cell lines were desirable, wherein all the drug–cell line pairs exhibited synergistic effects. The combinations with EGFR inhibitors exhibited different effects in two NSCLC cell lines. Therefore, all the combinations with osimertinib, gefitinib, erlotinib, or afatinib demonstrated antagonism in PC-9 cells harboring EGFR deletion (E746-A750), whereas the YHO-1701/osimertinib combination was synergistic in NCI-H1975 (hereinafter “H1975”) cells harboring the EGFR mutation L858R plus T790M.

Mechanistic analyses of synergistic effects *in vitro*.

Of particular interest was the synergistic effect observed when YHO-1701 was combined with imatinib against SUP-B15 cells (BCR-ABL fusion), with osimertinib against H1975 cells (L858R/T790M EGFR double-mutant), and with alectinib against NCI-H2228 (hereinafter “H2228”) cells (EML4-ALK fusion) based on the median-effect method (Fig. 2) and the potential clinical use. Dose-response curves of YHO-1701 and/or imatinib in SUP-B15 cells, osimertinib in H1975, or alectinib in H2228 cells, and their respective combination index (CI) values are shown in Figs. 3A, 4A, and 5A; moreover, the cell viability of all the combinations can be found in supplementary Table S1. To assess whether YHO-1701 and the combination partners are capable of inhibiting each target molecule at an earlier time point, cells were treated with single agents or their combination for 24 h. As expected, imatinib, osimertinib, and alectinib clearly suppressed their relevant molecules in each cell line (Figs. 3B, 4B, and 5B). Furthermore, YHO-1701 downregulated p-STAT3 expression in all cancer cell lines, consistent with the previous observation that YHO-1701 also inactivated the STAT3 signaling pathway in SAS cells⁸.

It has been reported that the third-generation EGFR inhibitor osimertinib, but not first- or second-generation EGFR inhibitors gefitinib, erlotinib, or afatinib, is active against exon 19 and 21 mutations as well as the T790M mutation-positive disease^{21–25} and that the efficacy of EGFR inhibitors in EGFR-mutation NSCLC is limited by other salvage signals, including STAT3 and Src-YES-associated protein 1 (YAP1) signaling²⁶. Reportedly, osimertinib failed to inhibit STAT3 signaling in EGFR^{L858R/T790M} mutant-expressing H1975 cells²⁶. In accordance with this finding, osimertinib failed to suppress p-STAT3 in H1975 cells (Fig. 4B) and we herein demonstrated that combined treatment with osimertinib and YHO-1701 induced synergistic tumor growth inhibition (Figs. 2 and 4A). These findings corroborate a role of STAT3 signaling in providing a better therapeutic advantage against T790M mutation-positive NSCLC. Whereas, we preliminary confirmed that PC-9 cells have absent STAT3 activity measured by western blot analysis in agreement with the article where PC-9 cells did not exhibit STAT3 activity²⁷, providing the main reason behind the different combination effects with osimertinib and YHO-1701 between PC-9 and H1975 cells (Fig. 2).

Although YHO-1701 induced p-AKT upregulation in H2228 cells, we did not observe any significant increase in the downstream target survivin level; conversely, it was lower than that in the vehicle-treated group (Fig. 5B). The survivin level was believed to be offset, since YHO-1701 was also capable of suppressing survivin, consistent with our previous observation where it was abrogated through inhibiting STAT3 dimerization and/or STAT3 phosphorylation⁸. In contrast to the moderate suppressions by single-drug treatments, the combination treatments strongly inhibited survivin levels in all sets (Figs. 3B, 4B, and 5B). After this experiment, we selected the “YHO-1701/alectinib + H2228” pair for the *in vivo* analysis based on particular research interests and the potential clinical use in order to conduct the further testing of drug combination.

YHO-1701 enhanced alectinib antitumor activity in EML4-ALK fusion-positive H2228 xenograft model.

We next evaluated whether YHO-1701 could enhance the antitumor effect of 2 mg/kg (Fig. 6A–C) or 4 mg/kg (Fig. 6D–F) of alectinib in H2228 xenograft mice. Our data revealed that 2 and 4 mg/kg of alectinib exhibited significant but different levels of antitumor responses with IR values of 31.2% and 61.1%, respectively ($p < 0.01$). In other words, although 2 mg/kg of alectinib delayed the tumor growth compared to that in the vehicle group, the tumors remained larger during the experimental period (Fig. 6A). In contrast, the average tumor volume remained almost stable in the 4 mg/kg group (Fig. 6D). Compared with the vehicle group on day 26, YHO-1701 alone exerted a moderate antitumor effect with an IR value of 24.0% (Fig. 6B,E). The plasma levels of YHO-1701 were higher than its *in vitro* IC₅₀ value against H2228 cells for approximately 18 h and at least 24 h in mice that received single and 5-day repeated doses, respectively (Supplementary Fig. S1). YHO-1701 inhibited *in vitro* proliferation of H2228 cells with an IC₅₀ value of $< 10 \mu\text{M}$ at 72 h, whereas the oral pharmacokinetic parameters in mice indicated that at the maximum plasma drug concentration (C_{max}), the concentration of YHO-1701 was 17.7-fold higher with single dosing and 26.5-fold higher with repeated dosing than this IC₅₀ value (Supplementary Fig. S1), suggesting adequate *in vivo* exposure to the compound. Adding YHO-1701 to alectinib resulted in superior tumor growth inhibitions to those observed in the respective monotherapy groups. The combination regimen led to 58.3% (Fig. 6B) and 79.2% (Fig. 6E) inhibition of H2228 tumor xenografts, which is suggestive of a potent combination efficacy even under the conditions that alectinib monotherapy demonstrated broad-spectrum antitumor effects.

The body weight of H2228-bearing mice in the vehicle group decreased gradually, accompanied by tumor growth, similar to that observed in tumor-associated cachexia. Importantly, the H2228 xenograft-induced body weight loss was alleviated in the combination group because of tumor growth inhibition without exhibiting systemic toxicity (Fig. 6C,F). Moreover, no adverse effects in general conditions or any treatment related macroscopic changes in major organs were induced by this therapeutically effective combination therapy, consistent with our previous observation⁸. These results indicate that this combination is effective for the treatment of EML4-ALK fusion-positive H2228 tumors and is not attributed to systemic toxicity.

Finally, we assessed the levels of survivin (the downstream target oncogene in the ALK and STAT3 pathways) in tumor tissues. In accordance with the *in vitro* analysis, alectinib 4 mg/kg and YHO-1701 monotherapies exhibited moderate suppression of survivin levels, despite the lack of significance. Moreover, survivin suppression level was superior with the combination compared to that with either single agent (Fig. 7).

Discussion

We have previously discovered the STAT3 inhibitor YHO-1701, which exhibited a multistep regulation in the STAT3 signaling pathway by blocking the dimerization of STAT3, and demonstrated a strong antiproliferative effect and combination effect using the multikinase inhibitor sorafenib in cancer cell lines and in a human oral carcinoma SAS tumor xenograft model⁸. In response to this finding, we were

interested in addressing whether the combination effect is applicable in subsequent situations with a diverse panel of molecular-targeted agents for hematologic or solid malignancies.

Here we observed additive or synergistic effects in almost two-thirds of the total number of “combination + cell line” sets given. Considering the use in clinical practice, of particular interest was the synergistic effect observed when YHO-1701 was combined with imatinib, dasatinib (BCR-ABL inhibitors), osimertinib (EGFR inhibitor), crizotinib, alectinib, or ceritinib (ALK inhibitors). Compared with the moderate suppressions by single-drug treatments, the combination treatments strongly and reproducibly suppressed the major downstream molecule survivin in all sets (Figs. 3B, 4B, and 5B).

Based on our *in vitro* observations, we next explored the *in vivo* combination activity on the “YHO-1701/alectinib + H2228” set. Despite recent advances in research, the treatment regimen for EML4–ALK-positive patients with NSCLC remains unsatisfactory. For example, despite the fact that the NSCLC cell lines H3122 and H2228 harbor EML4–ALK, the antiproliferative efficacy of the ALK inhibitor TAE684 or crizotinib and ALK siRNA was insufficient against H2228 cells^{28,29}. Furthermore, another research group emphasized the importance of dual interruption of STAT3 and ERK signaling pathways in H2228 cells⁹, and we agree with their statement. In this study, we found that crizotinib and alectinib inhibited p-ERK, and the addition of the STAT3 inhibitor YHO-1701 to these agents resulted in a greater downregulation of the STAT3-survivin signaling pathway and beneficial antiproliferative effects in H2228 cells (Figs. 2, 5, and S2). Meanwhile, crizotinib did not affect p-AKT (Fig. S2), consistent with the findings that neither TAE684 nor EML4–ALK depletion had a marked effect on p-AKT in H3122 or H2228 cells (“high” or “low” sensitive to ALK inhibition)⁹. This result implies that the AKT signal does not necessarily play a crucial role in the proliferation of these cancer cells; these findings support the present result that although YHO-1701 induced the upregulation of p-AKT in H2228 cells, it resulted in a clear growth inhibition. Moreover, sensitivity to ALK inhibitors is diminished by growth factors such as hepatocyte growth factor³⁰. In fact, another study showed that MET signal salvaged the growth of H3122 and H2228 cells after treatment with alectinib, and its combination with a MET inhibitor, PHA-66752, potentiated the efficacy of alectinib³¹. Based on this finding, we anticipated that synergy will occur via STAT3 inhibition because STAT3 is known to be a more downstream point of convergence for various growth factors^{31–34}. As expected, we confirmed that the addition of YHO-1701 to alectinib exhibited a promising combination effect against H2228 xenografts, where multiple factors in the tumor microenvironment can influence drug sensitivity. Additionally, this strategy may also be applicable in combination with other ALK inhibitors (i.e., crizotinib and ceritinib) judging from their CI values that were comparable with that of alectinib combination (Fig. 2).

To gain a better understanding of the contribution of YHO-1701 to enhance the antitumor properties of alectinib, YHO-1701 was combined with different doses of alectinib. The combination therapy of YHO-1701 with alectinib was found to be significantly effective against H2228 xenografts under both conditions where the tumors remained larger and almost stable throughout the experimental period with alectinib monotherapy (Fig. 6A,D). This indicates that YHO-1701 offers an ideal and practical

combination efficacy when used in combination with alectinib. Remarkably, in contrast with monotherapies, YHO-1701 plus alectinib diminished survivin levels in tumor tissues, suggesting that the superior antitumor activity of this combination is, at least partially, attributable to this downregulation. Regarding survivin, some studies have shown its potential characteristics as a useful biomarker^{35,36}. We believe that a series of experimental results, including our previous data, could render survivin a promising marker in YHO-1701 treatment⁸. Our study has demonstrated additive or synergistic effects in two-thirds of the “combination + model” sets; however, the underlying mechanisms responsible for the combination effect remain to be completely elucidated. We still believe that the other combinations are also worth further investigation.

Our study has a few limitations worth noting such as the use of cell line-based experiments. It is well known that cell lines are basically selected under the typical two-dimensional cell culture conditions³⁷. Nevertheless, patient-derived cancer cells (PDCs) used in three-dimensional spheroid cultures have advantages, as they often preserve the characteristics of the original tumor, including heterogeneity and complexity^{38,39}. As PDCs can also be applied to patient-derived xenograft models, further studies of YHO-1701 are of great interest. The next limitation is the small number of cell lines. Although we used 17 cell lines overall, the numbers for each type of cancer are relatively low because the access to cell lines from rare disease patients is limited. That being said, to our knowledge, our study reports the first evidence of a successful combination therapy of ALK and STAT3 inhibitors against EML4-ALK fusion-positive NSCLC *in vivo* model, which is potentially beneficial information for this patient population.

In conclusion, we clearly demonstrated that the antiproliferative activity of the combination of the novel STAT3 inhibitor YHO-1701 and a broad spectrum of mechanistically different targeted agents was markedly greater than that of the respective agent alone. Although it is important to validate our findings using clinical specimens, our data suggest that the logical strategy of the combination of YHO-1701 with other mechanistically different targeted agents could be a promising approach for treating patients with cancer in the future.

Materials And Methods

Human cancer cell lines.

The cell lines used in this study are listed in supplementary Table S2; they were maintained according to the supplier's instructions. Cultured cells were routinely tested for mycoplasma contamination using MycoAlert™ (Lonza, Walkersville, MD).

Chemicals, antibodies, and reagents.

YHO-1701 and gefitinib were synthesized at Yakult Honsha Co., Ltd. Other molecular-targeted agents were purchased based on their use in clinical practice and particular research interests for the combination experiments and are listed in supplementary Table S3. In the *in vitro* assays, these agents were dissolved in dimethyl sulfoxide (DMSO). The final DMSO concentration was adjusted to 0.1%. In the *in vivo* study,

YHO-1701 and alectinib were suspended in 0.5% methyl cellulose 400 cp solution and 0.5% HPMC/1 $\mu\text{mol/L}$ hydrochloric acid (HCl) solution, respectively. Supplementary Table S4 lists the antibodies. HCl solution was purchased from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan). All other reagents were obtained from Sigma-Aldrich (St. Louis, MO), unless otherwise specified.

Dose-response curves for IC₅₀ determination.

Dose-response curves were generated to determine the inhibitory concentration to achieve 50% cell death (IC₅₀ values). Briefly, cells were grown overnight in 96-well plates and then left untreated or treated with test articles at various concentrations prepared by serial dilutions. After 48 or 72 h, the extent of cell viability was assessed by the WST-8 dye-based assay (Kishida chemical, Osaka, Japan) as described previously⁴⁰. For each treatment condition, the mean values from triplicate wells were calculated and the dose-response curves plotted.

Drug combination studies.

The median-effect method was used to analyze the combination effects of YHO-1701 with molecular-targeted drugs comprising a diverse panel of standard-of-care agents⁴¹. To be specific, of the EGFR inhibitors tested, gefitinib, erlotinib, and afatinib are not clinically available for the treatment of patients with T790M mutation in exon 20 of EGFR (H1975 cells). Whereas, osimertinib is the standard therapy for treatment of NSCLC patients with acquired EGFR T790M mutation, and its use is not limited to PC-9 cells harboring EGFR deletion (E746-A750). The same goes for other drug-cell line pairs and this is the exact reason why the number of combinations is different among cell lines.

Briefly, test articles were combined in the same ratios in which both agents were prepared at a series of concentrations ranging from 4 $\times$, 2 $\times$, 1 $\times$, 0.5 $\times$, and 0.25 $\times$ for IC₅₀ values plus 0.1% DMSO alone. The nature of the interaction between both drugs was assessed under the condition that cells were treated simultaneously for 48 or 72 h. The antiproliferative potential of the combination over a concentration range was compared to that obtained for each agent alone, and a measure of the synergy, referred to as the CI, was calculated using a median-effect mathematical algorithm⁴¹. CalcuSyn (Biosoft, Ferguson, MO) was used to calculate CI values. $\text{CI} \leq 0.9$, $0.9 - 1.1$, and > 1.1 represent synergism, additive effect, and antagonism, respectively. Triplicate wells were set up for each treatment condition.

Western blotting.

For analyzing the phosphorylation/activation pattern of relevant molecules, cancer cells were treated with YHO-1701 and/or imatinib, osimertinib, or alectinib for 24 h; following this, they were lysed using RIPA buffer containing protease and phosphatase inhibitors (Nacalai Tesque, Inc., Kyoto, Japan). Lysate concentrations were determined using the BCA protein assay kit (Pierce Chemical Co., Rockford, IL) and normalized for protein load. The lysate was then separated on SDSpolyacrylamide gel electrophoresis gels and transferred onto polyvinylidene fluoride membranes. The membrane was treated with primary antibodies overnight at 4 °C. Proteins were detected using horseradish peroxidaseconjugated secondary

antibodies, visualized with an ECL kit (GE Healthcare Biosciences), and exposed to LAS-3000 (GE Healthcare Biosciences).

Evaluation of antitumor activity *in vivo*.

The antitumor efficacy of YHO-1701 in combination with alectinib was investigated in an H2228 xenograft model. Male BALB/c nude mice aged 6 weeks were purchased from Japan SLC, Inc. (Shizuoka, Japan). Tumor cells were inoculated subcutaneously into the right dorsal region of mice. When the mean tumor volume reached approximately 50–100 mm³ (day 1), they were randomly allocated to the following groups (n = 7): a vehicle group; a YHO-1701 monotherapy group (80 mg/kg); an alectinib monotherapy group (2 or 4 mg/kg alectinib); and a combination group. Treatment was started on day 1; the test compounds were administered orally using a 5-day-on/2-day-off × 4 cycle schedule. Tumor growth was monitored until day 26 by measuring two perpendicular diameters using a digital caliper (Mitutoyo, Kanagawa, Japan), and tumor volume was calculated as described earlier^{42,43}. On day 26, xenograft tumors were weighed and snap-frozen 24 h after the last dose for proof-of-concept study (see below). The antitumor efficacy was expressed based on tumor weight at day 26 as the percentage tumor growth inhibition (% IR), which was calculated using the formula $IR (\%) = (1 - \text{mean weight of the treated tumor} / \text{mean tumor weight in the vehicle group}) \times 100$. The body weight was monitored twice a week to assess tolerability to the combination therapy. The relative body weight (RBW) at day n was calculated using the following formula: $RBW = \text{body weight on day n} / \text{body weight on day 1}$.

The plasma YHO-1701 concentrations were determined with LC-MS/MS as described previously⁸. Briefly, non-tumor-bearing mice were orally administered either single (n = 3) or 5-day repeated (n = 6) doses of YHO-1701 at 80 mg/kg, and the values of C_{max} were calculated using the mean values.

Dose level of alectinib *in vivo*.

Here, we selected relatively low doses of alectinib to identify the optimal combination that might otherwise have been visualized by more predominant antitumor responses at higher dose levels. Therefore, we did not focus on comparative activities and toxicity of monotherapy in this study.

Proof-of-concept in tumor xenografts.

The enzyme-linked immunosorbent assay (ELISA) of survivin, Pathscan® Total Survivin Sandwich ELISA (Cell Signaling Technology, Beverly, MA) was used according to the manufacturer's instructions. Briefly, tumor lysates were prepared in the same buffer that was used for western blotting. Lysates were adjusted to a concentration of 10 mg/mL protein, and an equal amount (100 µL/well) of total protein from each sample was incubated overnight at 4 °C. After washing the plate, the detection antibody (100 µL/well) was added and incubated at 37 °C for 1 h. Binding was detected using horseradish peroxidase-linked streptavidin antibody and TMB substrate solution. The reaction product was measured at 450 nm (SpectraMax Plus 384, Molecular Devices Corp., Sunnyvale, CA). The survivin level was quantified and represented as the percentage of the vehicle group.

Statistical analysis.

Data are presented as mean $\pm$ standard deviation (SD). Statistical analyses were performed using the SAS System Release 8.2 software (SAS Preclinical Package, Version. 5.0, SAS Institute Japan Ltd., Tokyo, Japan) for tumor weight or the JMP software (version 14.3.0, SAS Institute Japan Ltd.) for survivin levels in tumor tissues. Either a Tukey's test or a Steel–Dwass test (Bartlett's test; $p < 0.05$) was used for detecting statistical differences between individual groups. P values < 0.05 were considered statistically significant.

Ethics statement.

All animal studies were conducted in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited facility in accordance with the Guidelines of the Yakult Central Institute and protocols approved by the Animal Experimental Committee of the Yakult Central Institute (#18–0021; approved May 31, 2018). All animal work was performed in accordance with Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines and regulations.

Declarations

Ethics statement.

All animal studies were conducted in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited facility in accordance with the Guidelines of the Yakult Central Institute and protocols approved by the Animal Experimental Committee of the Yakult Central Institute (#18-0021; approved May 31, 2018). All animal work was performed in accordance with Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines and regulations.

Acknowledgments

The authors thank Drs. Takeshi Matsuzaki, Ryuta Yamazaki, and Akinobu Kurita and Messrs. Satoru Ishii, Takahiro Iijima, and Takahito Miura for useful discussions. We are also grateful to Ms. Rika Morita for technical assistance.

Author contributions

K.T., M.T., and H.T. conceived and designed the study. K.T., H.K., A.Y., and M.T. conducted the experiments. K.T. provided data analysis and wrote the original draft. H.T., F.N., Y.S., and A.A. supervised the research. All authors read and approved the final manuscript.

Competing Interests

K.T., H.K., A.Y., M.T., H.T., F.N., and Y.S. are full-time employees of Yakult Honsha Co., Ltd., Tokyo, Japan. A.A. declares no competing interests.

References

- 1 Wang X, Crowe PJ, Goldstein D, Yang JL. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (Review). *Int J Oncol.* **41**, 1181-1191, <https://doi.org/10.3892/ijo.2012.1568> (2012).
- 2 Zhang HF, Lai R. STAT3 in cancer-friend or foe? *Cancers.* **6**, 1408-1440, <https://doi.org/10.3390/cancers6031408> (2014).
- 3 Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: New and unexpected biological functions. *Nat Rev Cancer.* **14**, 736-746, <https://doi.org/10.1038/nrc3818> (2014).
- 4 Levy DE, Lee CK. What does Stat3 do? *J. Clin Invest.* **109**, 1143-1148, <https://doi.org/10.1172/JCI15650> (2002).
- 5 Bromberg JF, *et al.* Stat3 as an oncogene. *Cell.* **98**, 295-303, [https://doi.org/10.1016/S0092-8674\(00\)81959-5](https://doi.org/10.1016/S0092-8674(00)81959-5) (1999).
- 6 Yang XO, *et al.* STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. *J Biol Chem.* **282**, 9358-9363, <https://doi.org/10.1074/jbc.C600321200> (2007).
- 7 Aggarwal BB, *et al.* Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer. *Ann NY Acad Sci.* **1091**, 151-169, <https://doi.org/10.1196/annals.1378.063> (2006).
- 8 Nishisaka F, *et al.* Antitumor activity of a novel oral signal transducer and activator of transcription 3 inhibitor YHO-1701. *Cancer Sci.* **111**, 1774-1784, <https://doi.org/10.1111/cas.14369> (2020).
- 9 Tanizaki J, *et al.* Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells. *Br J Cancer.* **160**, 763-767, <https://doi.org/10.1038/bjc.2011.586> (2012).
- 10 Bayliss R, Choi J, Fennell DA, Fry AM, Richards MW. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. *Cell Mol Life Sci.* **73**, 1209-1224, <https://doi.org/10.1007/s00018-015-2117-6> (2016).
- 11 Choi YL, *et al.* EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N Engl J Med.* **363**, 1734-1739, <https://doi.org/10.1056/NEJMoa1007478> (2010).
- 12 Sasaki T, *et al.* A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. *Cancer Res.* **71**, 6051-6060, <https://doi.org/10.1158/0008-5472.CAN-11-1340> (2011).
- 13 Doebele RC, *et al.* Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. *Clin Cancer Res.* **18**, 1472-1482, <https://doi.org/10.1158/1078-0432.CCR-11-2906> (2012).

- 14 Katayama R, *et al.* Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. *Sci Transl Med.* **4**, 120ra117, <https://doi.org/10.1126/scitranslmed.3003316> (2012).
- 15 Rolfo C, *et al.* ALK and crizotinib: after the honeymoon...what else? Resistance mechanisms and new therapies to overcome it. *Transl Lung Cancer Res.* **3**, 250-261, <https://doi.org/10.3978/j.issn.2218-6751.2014.03.01> (2014).
- 16 Miyawaki M, *et al.* Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer. *Mol Cancer Res.* **15**, 106-114, <https://doi.org/10.1158/1541-7786.mcr-16-0211> (2017).
- 17 Crystal AS, *et al.* Patient-derived models of acquired resistance can identify effective drug combinations for cancer. *Science.* **346**, 1480-1486, <https://doi.org/10.1126/science.1254721> (2014).
- 18 Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. *Blood.* **101**, 1535-1542, <https://doi.org/10.1182/blood-2002-07-2130> (2003).
- 19 Holbeck SL, *et al.* The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity. *Cancer Res.* **77**, 3564-3576, <https://doi.org/10.1158/0008-5472.CAN-17-0489> (2017).
- 20 Sidorov P, Naulaerts S, Arieu-Bonnet J, Pasquier E, Ballester PJ. Predicting synergism of cancer drug combinations using NCI-ALMANAC data. *Front Chem.* **7**, 509, <https://doi.org/10.3389/fchem.2019.00509> (2019).
- 21 Kobayashi S, *et al.* EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med.* **352**, 786-792, <https://doi.org/10.1056/NEJMoa044238> (2005).
- 22 Pao W, *et al.* Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med.* **2**, e73, <https://doi.org/10.1371/journal.pmed.0020073> (2005).
- 23 Sequist LV, *et al.* Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med.* **3**, 75ra26, <https://doi.org/10.1126/scitranslmed.3002003> (2011).
- 24 Yu HA, *et al.* Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. *Clin Cancer Res.* **19**, 2240-2247, <https://doi.org/10.1158/1078-0432.CCR-12-2246> (2013).
- 25 Remon J, Steuer CE, Ramalingam SS, Felip E. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. *Ann Oncol.* **29**, i20-i27, <https://doi.org/10.1093/annonc/mdx704> (2018).

- 26 Chaib I, *et al.* Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. *J Natl Cancer Inst.* **109**, djx014, <https://doi.org/10.1093/jnci/djx014> (2017).
- 27 Song L, Rawal B, Nemeth JA, Haura EB. JAK1 Activates STAT3 Activity in Non-Small-Cell Lung Cancer Cells and IL-6 Neutralizing Antibodies Can Suppress JAK1-STAT3 Signaling. *Mol Cancer Ther.* **10**, 481-494, <https://doi.org/10.1158/1535-7163.MCT-10-0502> (2011).
- 28 Rikova K, *et al.* Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. *Cell.* **131**, 1190-1203, <https://doi.org/10.1016/j.cell.2007.11.025> (2007).
- 29 Koivunen JP, *et al.* EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. *Clin Cancer Res.* **14**, 4275-4283, <https://doi.org/10.1158/1078-0432.CCR-08-0168> (2008).
- 30 Tanimoto A, *et al.* Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. *Oncotarget.* **5**, 4920-4928, <https://doi.org/10.18632/oncotarget.2055> (2014).
- 31 Kogita A, *et al.* Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer. *Int J Oncol.* **46**, 1025-1030, <https://doi.org/10.3892/ijo.2014.2797> (2015).
- 32 Ariyawutyakorn W, Saichaemchan S, Varella-Garcia M. Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet? *J Cancer.* **7**, 633-649, <https://doi.org/10.7150/jca.12663> (2016).
- 33 Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. *Oncogene.* **22**, 4150-4165, <https://doi.org/10.1038/sj.onc.1206479> (2003).
- 34 Mehta R, *et al.* Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells. *PLoS One.* **8**, e65113, <https://doi.org/10.1371/journal.pone.0065113> (2013).
- 35 Mahmoudian-Sani MR, Alghasi A, Saeedi-Boroujeni A, Jalali A, Jamshidi M, Khodadadi A. Survivin as a diagnostic and therapeutic marker for thyroid cancer. *Pathology Res Pract.* **215**, 619-625, <https://doi.org/10.1016/j.prp.2019.01.025> (2019).
- 36 Veiga GLD, *et al.* The role of Survivin as a biomarker and potential prognostic factor for breast cancer. *Rev Assoc Med Bras.* **65**, 893-901, <https://doi.org/10.1590/1806-9282.65.6.893> (1992).
- 37 Namekawa T, Ikeda K, Horie-Inoue K, Inoue S. Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells. *Cells.* **8**, 74, <https://doi.org/10.3390/cells8010074> (2019).
- 38 Kopetz S, Lemos R, Powis G. The promise of patient-derived xenografts: The best laid plans of mice and men. *Clin Cancer Res.* **18**, 5160-5162, <https://doi.org/10.1158/1078-0432.CCR-12-2408> (2012).

39 Daniel VC, *et al.* A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture *in vitro*. *Cancer Res.* **69**, 3364-3373, <https://doi.org/10.1158/0008-5472.CAN-08-4210> (2009).

40 Haibara H, *et al.* YPC-21661 and YPC-22026, novel small molecules, inhibit ZNF143 activity *in vitro* and *in vivo*. *Cancer Sci.* **108**, 1042-1048, <https://doi.org/10.1111/cas.13199> (2017).

41 Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. *Cancer Res.* **15**, 440-446, <https://doi.org/10.1158/0008-5472.CAN-09-1947> (2010).

42 Taniguchi K, Nishiura H, Ota Y, Yamamoto T. Roles of the Ribosomal Protein S19 Dimer and Chemically Induced Apoptotic Cells as a Tumor Vaccine in Syngeneic Mouse Transplantation Models. *J Immunother.* **34**, 16-27, <https://doi.org/10.1097/CJI.0b013e3181fb03ed> (2011).

43 Taniguchi K, Nishiura H, Yamamoto T. Requirement of the Acquired Immune System in Successful Cancer Chemotherapy with *cis*-Diamminedichloroplatinum (II) in a Syngeneic Mouse Tumor Transplantation Model. *J Immunother.* **34**, 480-489, <https://doi.org/10.1097/CJI.0b013e31821e7662> (2011).

Figures

Figure 1

Schematic representation of the mechanism of growth inhibition by YHO-1701 and other molecular-targeted drugs. Abbreviations: HER2, human epidermal growth factor receptor 2; JAK, Janus kinase; PI3K, phosphatidylinositol 3-kinase; AKT, protein kinase B; mTOR, mammalian target of rapamycin; MEK, mitogen-activated protein kinase kinase; ERK, extracellular signal-regulated kinase. Blunt arrows show molecular-targeted agents inhibiting relevant pathways.

Tumor type	Combination partner	Target	Cell line	CI
CML	Imatinib	BCR-ABL	K562	
	Dasatinib			
ALL	Imatinib		SUP-B15	
	Dasatinib			
NSCLC	Crizotinib	ALK	H2228	
	Alectinib			
	Ceritinib			
	Osimertinib	EGFR	H1975	
	Gefitinib		PC-9	
	Erlotinib			
	Afatinib			
Breast cancer	Lapatinib	HER2/EGFR	SK-BR-3	
			BT-474	
	Everolimus	mTOR	MCF-7	
Oral cancer	Sorafenib	Multikinase	SAS	
Thyroid cancer	Sorafenib		K1	
			FTC-133	
	Vandetanib		K1	
			FTC-133	
Colon cancer	Regorafenib		COLO205	
			HCT-15	
Melanoma	Trametinib		MEK	SK-MEL-5
		SK-MEL-28		
		A375		
		A2058		
	Vemurafenib	BRAF	SK-MEL-5	
			SK-MEL-28	
			A375	
			A2058	
	Dabrafenib		SK-MEL-28	
			A375	
			A2058	

synergy

Color Key

antagonism

$CI \leq 0.10$

$0.10 < CI \leq 0.30$

$0.30 < CI \leq 0.70$

$0.70 < CI \leq 0.85$

$0.85 < CI \leq 0.90$

$0.90 < CI \leq 1.10$

$1.10 < CI \leq 1.20$

$1.20 < CI \leq 1.45$

$1.45 < CI \leq 3.30$

$3.30 < CI \leq 10.0$

$10.0 < CI$

Figure 2

In vitro synergy of YHO-1701 in combination with already-available targeted agents for a total of 33 “combination + cell line” pairs. Drug interactions (synergism or antagonism) were analyzed using the combination index (CI) method. The antiproliferative effect of YHO-1701 and/or molecular-targeted agents was evaluated in a human cancer cell line panel using the WST-8 assay at 48 or 72 h of exposure. CI values were calculated and represented as a synergy “heat map” where a drug combination is synergistic (pink color) if $CI \leq 0.9$; additive (white color) if CI is 0.9–1.1; and antagonistic (gray color) if $CI > 1.1$.

Figure 3

Synergism between YHO-1701 and imatinib in SUP-B15 cells. (A) The antiproliferative effect of YHO-1701 and/or imatinib was evaluated at 72 h of exposure. Dose-response curves are shown in the left panel. Combination index (CI) values are plotted as a function of fraction affected (Fa) in the right panel. (B) Phosphorylation/activation pattern of crucial molecules on BCR-ABL and STAT3 signaling pathways were analyzed by western blotting. SUP-B15 cells were left untreated or treated with YHO-1701 and/or imatinib at indicated doses for 24 h. The blots were probed with primary antibodies specific for the target proteins. Images were cropped for clarity, and full-length blots are presented in Supplementary Fig. S3.

Figure 4

Synergism between YHO-1701 and imatinib in SUP-B15 cells. (A) The antiproliferative effect of YHO-1701 and/or imatinib was evaluated at 72 h of exposure. Dose-response curves are shown in the left panel. Combination index (CI) values are plotted as a function of fraction affected (Fa) in the right panel. (B) Phosphorylation/activation pattern of crucial molecules on BCR-ABL and STAT3 signaling pathways were analyzed by western blotting. SUP-B15 cells were left untreated or treated with YHO-1701 and/or imatinib at indicated doses for 24 h. The blots were probed with primary antibodies specific for the target proteins. Images were cropped for clarity, and full-length blots are presented in Supplementary Fig. S3.

Figure 5

Synergism between YHO-1701 and alectinib in H2228 cells. (A) The antiproliferative effect of YHO-1701 and/or alectinib was investigated at 72 h of exposure. Dose-response curves are represented in the left panel. Combination index (CI) values are plotted as a function of fraction affected (Fa) in the right panel. (B) Phosphorylation/activation pattern of key molecules on ALK and STAT3 signaling pathways were examined by western blotting. H2228 cells were left untreated or treated with YHO-1701 and/or alectinib at indicated doses for 24 h. The blots were probed with the respective primary antibodies. Cropped images are shown, and full-length blots are presented in Supplementary Fig. S3.

Figure 6

In vivo characterization of orally administered YHO-1701 when combined with alectinib at different levels of efficacy. Alectinib was used at 2 mg/kg/day (A-C) or 4 mg/kg/day (D-F). H2228 xenograft mice were randomized on day 1. Mice were treated with vehicle, YHO-1701, alectinib, or YHO-1701 + alectinib once daily for 4 weeks using a 5-day on, 2-day off schedule at indicated doses (n = 7). Changes in tumor volume (A, D), tumor weight on day 26 (B, E), and relative body weight (C, F). Significance was determined by Tukey's test (B) or Steel–Dwass test (E). * p < 0.05; ** p < 0.01; *** p < 0.001 versus the vehicle group. † p < 0.05; †† p < 0.01 versus the alectinib group. †† p < 0.01 versus the YHO-1701 group. Abbreviations: mpk, milligrams per kilogram of body weight; YHO, YHO-1701.

Figure 7

Downregulation of downstream target survivin in tumor tissues. Lysates prepared from H2228 xenografts in Fig. 6E were subjected to further analyses. Survivin levels were determined by ELISA. Significance was determined by Tukey's test. * $p < 0.05$ versus the vehicle group. Abbreviations: mpk, milligrams per kilogram of body weight; YHO, YHO-1701.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryDatasetTaniguchietal..pdf](#)